These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 32207274

  • 1. Comparison of the Efficacy and Safety of Insulin Detemir Administered Once Daily According to Two Titration Algorithms (3-0-3 and 2-4-6-8) in Patients with Type 2 Diabetes Mellitus.
    Yu HM, Park KS, Hong JH, Park KY, Lee JM, Ku BJ, Kim YJ, Oh TK.
    Endocrinol Metab (Seoul); 2020 Mar; 35(1):142-148. PubMed ID: 32207274
    [Abstract] [Full Text] [Related]

  • 2. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
    Blonde L, Merilainen M, Karwe V, Raskin P, TITRATE Study Group.
    Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
    [Abstract] [Full Text] [Related]

  • 3. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries.
    Khunti K, Caputo S, Damci T, Dzida GJ, Ji Q, Kaiser M, Karnieli E, Liebl A, Ligthelm RJ, Nazeri A, Orozco-Beltran D, Pan C, Ross SA, Svendsen AL, Vora J, Yale JF, Meneghini LF, SOLVE Study Group.
    Diabetes Obes Metab; 2012 Dec; 14(12):1129-36. PubMed ID: 22830956
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of Age on Glycemic Control in Patients With Type 2 Diabetes Treated with Insulin Detemir: A Post-Hoc Analysis of the PREDICTIVE™ 303 Study.
    Bhargava A, Chan V, Kimball ES, Oyer DS.
    Drugs Aging; 2016 Feb; 33(2):135-41. PubMed ID: 26833348
    [Abstract] [Full Text] [Related]

  • 7. Comparable efficacy with similarly low risk of hypoglycaemia in patient- vs physician-managed basal insulin initiation and titration in insulin-naïve type 2 diabetic subjects: The Italian Titration Approach Study.
    Bonadonna RC, Giaccari A, Buzzetti R, Perseghin G, Cucinotta D, Avogaro A, Aimaretti G, Larosa M, Fanelli CG, Bolli GB.
    Diabetes Metab Res Rev; 2020 Sep; 36(6):e3304. PubMed ID: 32118347
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial.
    Halberg IB, Lyby K, Wassermann K, Heise T, Zijlstra E, Plum-Mörschel L.
    Lancet Diabetes Endocrinol; 2019 Mar; 7(3):179-188. PubMed ID: 30679095
    [Abstract] [Full Text] [Related]

  • 10. Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes.
    Nimri R, Lebenthal Y, Shalitin S, Benzaquen H, Demol S, Phillip M.
    Pediatr Diabetes; 2013 May; 14(3):196-202. PubMed ID: 23289822
    [Abstract] [Full Text] [Related]

  • 11. Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3).
    Rodbard HW, Tripathy D, Vidrio Velázquez M, Demissie M, Tamer SC, Piletič M.
    Diabetes Obes Metab; 2017 Oct; 19(10):1389-1396. PubMed ID: 28345792
    [Abstract] [Full Text] [Related]

  • 12. Insulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (BOOST® : SIMPLE USE).
    Park SW, Bebakar WM, Hernandez PG, Macura S, Hersløv ML, de la Rosa R.
    Diabet Med; 2017 Feb; 34(2):174-179. PubMed ID: 26773557
    [Abstract] [Full Text] [Related]

  • 13. Comparison of two titration programmes for adding insulin detemir to oral antidiabetic drugs in patients with poorly controlled type 2 diabetes mellitus.
    Liu SC, Chuang SM, Wang CH, Chien MN, Lee CC, Chen WC, Leung CH, Lin JL.
    Diabetes Obes Metab; 2023 Mar; 25(3):700-706. PubMed ID: 36321411
    [Abstract] [Full Text] [Related]

  • 14. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, Bray R, Rodríguez Á.
    Lancet; 2021 Aug 14; 398(10300):583-598. PubMed ID: 34370970
    [Abstract] [Full Text] [Related]

  • 15. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S, Chow F, Choi DS, Taneda S, Hirao K, Park Y, Andersen TH, Gall MA, Christiansen JS, BOOST: Intensify All Trial Investigators.
    Diabetes Res Clin Pract; 2015 Jan 14; 107(1):139-47. PubMed ID: 25498130
    [Abstract] [Full Text] [Related]

  • 16. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
    Meneghini L, Koenen C, Weng W, Selam JL.
    Diabetes Obes Metab; 2007 Nov 14; 9(6):902-13. PubMed ID: 17924873
    [Abstract] [Full Text] [Related]

  • 17. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G.
    Diabetologia; 2008 Mar 14; 51(3):408-16. PubMed ID: 18204830
    [Abstract] [Full Text] [Related]

  • 18. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
    Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ, EMPA-REG BASALTM trial investigators.
    Diabetes Obes Metab; 2015 Oct 14; 17(10):936-48. PubMed ID: 26040302
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial.
    Harris SB, Kocsis G, Prager R, Ridge T, Chandarana K, Halladin N, Jabbour S.
    Diabetes Obes Metab; 2017 Jun 14; 19(6):858-865. PubMed ID: 28124817
    [Abstract] [Full Text] [Related]

  • 20. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S, Koenen C, Bode B.
    Clin Ther; 2009 Oct 14; 31(10):2086-97. PubMed ID: 19922879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.